Applying Key Updates from ESC/HFA to Managing Heart Failure - a podcast by ReachMD

CME credits: 0.25

Valid until: 23-11-2022

Claim your CME credit at https://reachmd.com/programs/cme/applying-key-updates-esc-hfa-managing-heart-failure/13026/

Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.

In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD